FDA's plan to diversify clinical trials falls flat, study finds

Five years ago, the Food and Drug Administration began implementing a plan to increase diversity and transparency in its clinical trials of medicines.

So what progress has been made? Well, not nearly enough, according to the reporting of Ed Silverman, a senior writer for STAT.